We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Recommends Nonclinical Trial Design for Osteoporosis Therapies
FDA Recommends Nonclinical Trial Design for Osteoporosis Therapies
Drugmakers seeking approval of osteoporosis candidates should bolster their submissions with nonclinical pharmacology studies to determine adverse effects, the FDA advises.